Trial Profile
18F‑Florbetaben (Neuraceq®) PET/MRI Evaluation of Cardiac Amyloid
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 25 Aug 2020
Price :
$35
*
At a glance
- Drugs Florbetaben F18 (Primary)
- Indications Amyloidosis
- Focus Diagnostic use
- 16 Jul 2019 Status changed from active, no longer recruiting to completed.
- 24 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 20 Apr 2017 New trial record